Canntab Therapeutics Limited
CTABF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -44.4% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -320.1% | – | 100% | 59.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -848% | – | -1,713.8% | -1,008.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,257.6% | – | -1,955.4% | -1,024.4% |
| EPS Diluted | -0.098 | -0.13 | -0.096 | -0.097 |
| % Growth | 24.8% | -35.4% | 1.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |